Allergan acquires NASH player Tobira for $1.695bn

15:40 EDT 22 Sep 2016 | Elsevier Business Intelligence

In the first of two acquisitions announced on the same day, both focused on the emerging non-alcoholic steatohepatitis (NASH) market, Allergan PLC bought publicly traded Tobira Therapeutics Inc. for $1.695bn, including approximately $534mm up front plus up to $1.2bn in earn-outs.

Original Article: Allergan acquires NASH player Tobira for $1.695bn


More From BioPortfolio on "Allergan acquires NASH player Tobira for $1.695bn"

Quick Search

Relevant Topic

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.